ANVS · Annovis Bio, Inc.
$1.72
-0.09 (-4.97%)
At close · Aug 28
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has concluded that substantial doubt exists about the Company's ability to continue as a going concern. Management's plans to mitigate this risk include raising additional capital through equity financings, debt, or other potential alternatives. Management's plans may also include the deferral of certain operating expenses unless and until additional capital is received. However, there can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to the Company, or that the Company will be successful in deferring certain operating expenses. As such, Management has concluded that such plans do not alleviate the aforementioned substantial doubt.”View the 10-Q filed Aug 14, 2026
Market Cap
$73.28M
Shares
42.61M
Fails to deliver — shares from a trade that were not delivered to the buyer by the settlement date — published by the SEC twice a month. Persistent fails can reflect settlement problems or naked short selling.
Fails to Deliver History
| Settlement Date | Quantity | Price | Value |
|---|---|---|---|
| 2026-07-21 | 4,906 | $1.69 | $8,291 |
| 2026-07-07 | 528 | $1.97 | $1,040 |
| 2026-07-06 | 744 | $1.93 | $1,436 |
| 2026-07-01 | 597 | $1.86 | $1,110 |
| 2026-06-30 | 600 | $1.86 | $1,116 |
| 2026-06-26 | 13,239 | $1.65 | $21,844 |
| 2026-06-25 | 3,185 | $1.70 | $5,415 |
| 2026-06-17 | 3,337 | $1.79 | $5,973 |
| 2026-06-12 | 6,000 | $1.83 | $10,980 |
| 2026-06-11 | 17,918 | $1.72 | $30,819 |
| 2026-06-10 | 14,226 | $1.77 | $25,180 |
| 2026-06-09 | 3,166 | $1.79 | $5,667 |
| 2026-06-08 | 36 | $1.89 | $68 |
| 2026-05-29 | 121 | $1.90 | $230 |
Showing 1–14 of 14 settlements
Key facts
CIK
1477845
CUSIP
03615A108
13F (30d)
55 filings
53 filers
Visit website
Investor relations